Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin
Clinical Infectious Diseases · 30.04.2026 · 82 (4) · e720-e727
DOI: 10.1093/cid/ciaf732 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 30.12.2025. Verfasst von Emmanuella Chinonso Osuala und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South …. Hauptthemen laut MEDLINE: HIV Infections, Tenofovir, Adenine, Tuberculosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, FIC NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Background
Tenofovir alafenamide (TAF) is a key component of many fixed-dose combinations used to treat HIV. There are limited data on the pharmacokinetics of plasma TAF, tenofovir (TFV), or intracellular tenofovir diphosphate (TFV-DP), among people with HIV (PWH) and tuberculosis (TB) who are taking rifampicin-based TB treatment.
Methods
Participants in the intervention arm of the INSIGHT trial (NCT04734652) receiving bictegravir/emtricitabine/TAF (BIC/FTC/TAF 50/200/25 mg) were enrolled into the semi-intensive pharmacokinetic substudy. BIC/FTC/TAF was administered twice-daily during rifampicin-based TB treatment (∼24 weeks) and once-daily thereafter. Plasma (TAF/TFV) and dried blood spot samples (TFV-DP) were collected at weeks 4 and 12 (predose, 1, 2, 4, 6, and 8–12 hours postdose) during TB treatment and at week 32 (predose, 1, 2, 4, 6–8 and 24–25 hours postdose) post-TB treatment. Pharmacokinetic parameters were determined using noncompartmental analysis. Clinical and safety data were collected.
Results
Among 43 participants enrolled; median (IQR) age and weight were 35 (30–39) years and 58 (52–65) kg; 77% were male. Geometric least square mean ratios (90% CI) at week 12 (twice-daily TAF) relative to week 32 (once-daily TAF) for TAF AUC0-4, TFV, and TFV-DP AUC0-24 were 1.55 (1.13–2.13), 1.24 (1.07–1.44), and 1.32 (1.13–1.53), respectively. At week 24, 95% of participants achieved viral suppression, with no treatment-related serious adverse events or drug discontinuations.
Conclusions
Twice-daily TAF was safe and efficacious and achieved similar exposures of intracellular TFV-DP in PWH taking rifampicin for TB compared to once-daily TAF taken alone. These data support the use of TAF in a fixed-dose combination of BIC/FTC/TAF during rifampicin-containing TB treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), South African Medical Research Council (SAMRC)-CAPRISA-TB-HIV Pathogenesis and Treatment Research Unit, University of KwaZulu-Natal Nelson R Mandela S…
- Medical Affairs, Gilead Sciences, Foster City, California, USA.
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
ORCID-Profile: Emmanuella Chinonso Osuala, Ivan Nicholas Nkuhairwe, Marothi Peter Letsoalo, Kogieleum Naidoo, Rubeshan Perumal, James F Rooney, Lubbe Wiesner, Roeland E Wasmann, Paolo Denti, Kelly E Dooley, Anushka Naidoo
Förderung
- NIAID NIH HHS
- FIC NIH HHS
- National Institute of Allergy and Infectious Diseases
- NIH HHS
- National Research Foundation Postgraduate Scholarship
- South African Medical Research Council
- Fogarty International Center
- National Institutes of Health
Zitieren
APA
Osuala, E. C., Nkuhairwe, I. N., Letsoalo, M. P., Naidoo, K., Perumal, R., Rooney, J. F., Wiesner, L., Wasmann, R. E., Denti, P., Dooley, K. E., Naidoo, A., & INSIGHT Study Team (2026). Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin. Clinical Infectious Diseases, 82(4), e720-e727. https://doi.org/10.1093/cid/ciaf732
Vancouver
Osuala EC, Nkuhairwe IN, Letsoalo MP, Naidoo K, Perumal R, Rooney JF, et al. Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin. Clinical Infectious Diseases. 2026;82(4):e720-e727. doi:10.1093/cid/ciaf732
BibTeX
@article{Osuala2026,
author = {Osuala, Emmanuella Chinonso and Nkuhairwe, Ivan Nicholas and Letsoalo, Marothi Peter and Naidoo, Kogieleum and Perumal, Rubeshan and Rooney, James F and Wiesner, Lubbe and Wasmann, Roeland E and Denti, Paolo and Dooley, Kelly E and Naidoo, Anushka and INSIGHT Study Team, INSIGHT Study Team},
title = {Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin},
journal = {Clinical Infectious Diseases},
year = {2026},
volume = {82},
number = {4},
pages = {e720--e727},
doi = {10.1093/cid/ciaf732}
}
EUVIMED